Johnson & Johnson

Longer-term MARIPOSA study data confirm RYBREVANT® plus LAZCLUZE™ regimen's superior outcomes over osimertinib monotherapy in first-line advanced NSCLC with EGFR ex19del or L858R mutations, showing consistent benefits and an 8% survival improvement at three years.

Johnson & Johnson announced that RYBREVANT (amivantamab-vmjw) combined with LAZCLUZE (lazertinib) provided consistent benefits over osimertinib in advanced NSCLC patients with EGFR exon 19 deletions or L858R mutations, with 61% survival at three years compared to 53% for osimertinib. The combination also showed improved central nervous system disease control and longer progression-free survival.

The Orphan Drugs Market is projected to grow from USD 225.9 Billion in 2023 to USD 493.21 Billion by 2031, driven by rising prevalence of rare diseases, unmet medical needs, favorable regulatory policies, technological advancements, and growing public and patient advocacy. Key challenges include high R&D costs, limited patient populations, pricing and reimbursement issues, and lack of long-term data. Trends include focus on gene therapies, personalized medicine, stakeholder collaboration, and expansion into emerging markets. North America leads the market, followed by Europe and Asia Pacific.

Prostate Cancer Treatment Market growth driven by rising incidence, awareness, and advances in technologies like immunotherapy and targeted biologics. Market expected to grow at 5.00% CAGR from 2024 to 2031, supported by healthcare infrastructure investments and personalized medicine.

The ultrasound and electrosurgical energy dissectors market is projected to reach $8.48 billion by 2028 with a CAGR of 7.1%, driven by factors like point-of-care diagnostics, robotic surgeries, and outpatient procedures. Key players include Johnson & Johnson, Medtronic, and Olympus Corporation. Market segments include ultrasound and electrosurgical devices, applications in cardiology, gynecology, and general surgery, and end-users such as hospitals and ambulatory surgical centers.

The WHO's mpox declaration led to significant stock market increases for pharmaceutical, medical tech, and biopharmaceutical companies, while airline stocks declined, reflecting investor concerns about mpox's global spread.